Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.44 |
| ▸ | RPS6KB1 | P23443 | 14/20 | 0.44 |
| ▸ | AKT1 | P31749 | 14/20 | 0.44 |
| ▸ | HTR2C | P28335 | 2/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.42 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.42 |
| ▸ | AKT2 | P31751 | 5/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.41 |
| ▸ | AKT3 | Q9Y243 | 5/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15720111 | 0.88 | RPS6KB1 (0.46) | RPS6KB1AKT1RPS6KA1TLR8AKT2 | |
| SCHEMBL15719892 | 0.88 | RPS6KB1 (0.41) | GABRA1GABRB2RPS6KB1AKT1RPS6KA1 | |
| Hydrochloric Acid SCHEMBL11903905 | 0.88 | RPS6KB1 (0.46) | RPS6KB1AKT1RPS6KA1TLR8AKT2 | |
| Hydrochloric Acid SCHEMBL11904052 | 0.87 | RPS6KB1 (0.41) | GABRA1GABRB2RPS6KB1AKT1RPS6KA1 | |
| SCHEMBL15720777 | 0.87 | RPS6KB1 (0.45) | GABRA1GABRB2RPS6KB1AKT1RPS6KA1 | |
| SCHEMBL15720450 | 0.87 | HTR2C (0.46) | RPS6KB1AKT1HTR2CRPS6KA1TLR8 | |
| Hydrochloric Acid SCHEMBL11904101 | 0.85 | MEN1 (0.49) | RPS6KB1AKT1HTR2CRPS6KA1TLR8 | |
| SCHEMBL17023911 | 0.84 | RPS6KB1 (0.51) | RPS6KB1AKT1 | |
| SCHEMBL15719613 | 0.83 | AKT1 (0.61) | RPS6KB1AKT1AKT2KCNH2AKT3 | |
| SCHEMBL17023907 | 0.83 | HTR1D (0.45) | GABRA1RPS6KB1AKT1RPS6KA1TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3299362-B1 | IMIDAZOL-PIPERIDINYL DERIVATIVES AS MODULATORS OF KINASE ACTIVITY | MERCK PATENT GMBH (DE) | 2020-04-22 | — | — | EP | disclosed |
| EP-3299362-A1 | IMIDAZOL-PIPERIDINYL DERIVATIVES AS MODULATORS OF KINASE ACTIVITY | Merck Patent GmbH (DE) | 2018-03-28 | — | — | EP | disclosed |
| US-9315517-B2 | Imidazol-piperidinyl derivatives as modulators of kinase activity | MERCK PATENT GMBH (DE) | 2016-04-19 | — | — | US | disclosed |
| EP-2920154-A1 | NOVEL IMIDAZOL-PIPERIDINYL DERIVATIVES AS MODULATORS OF KINASE ACTIVITY | Merck Patent GmbH (DE) | 2015-09-23 | — | — | EP | disclosed |
| US-20150239902-A1 | Novel Imidazol-piperidinyl Derivatives as Modulators of Kinase Activity | MERCK PATENT GMBH (DE) | 2015-08-27 | — | — | US | disclosed |
| WO-2014078634-A1 | NOVEL IMIDAZOL-PIPERIDINYL DERIVATIVES AS MODULATORS OF KINASE ACTIVITY | MERCK PATENT GMBH (DE) | 2014-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150239902-A1 | Novel Imidazol-piperidinyl Derivatives as Modulators of Kinase Activity | MAP4K2, MAP4K3, MAP3K4 | GABRA1 3198/4885GABRB2 2991/4885RPS6KB1 318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.